Literature DB >> 28337614

Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases.

Daniele Velardo1, Nilo Riva2, Ubaldo Del Carro3, Francesca Bianchi3, Giancarlo Comi2, Raffaella Fazio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28337614     DOI： 10.1007/s00415-017-8462-7

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  16 in total

1.  Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England.

Authors:  M P Lunn; H Manji; P P Choudhary; R A Hughes; P K Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

2.  Rituximab-responsive CIDP.

Authors:  C Briani; G Zara; R Zambello; L Trentin; M Rana; F Zaja
Journal:  Eur J Neurol       Date:  2004-11       Impact factor: 6.089

3.  Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.

Authors:  D Cocito; S Grimaldi; I Paolasso; Y Falcone; G Antonini; L Benedetti; C Briani; R Fazio; S Jann; S Matà; M Sabatelli; E Nobile-Orazio
Journal:  Eur J Neurol       Date:  2011-08-05       Impact factor: 6.089

4.  Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment.

Authors:  P G Sanz; C V García Méndez; A L Cueto; V B Silva; J C Walther; R A Diez; S Martins; R J Giannaula
Journal:  Rheumatol Int       Date:  2011-09-16       Impact factor: 2.631

Review 5.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Authors:  Panos Stathopoulos; Harry Alexopoulos; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

6.  Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.

Authors:  Adele D'Amico; Michela Catteruccia; Fabrizio De Benedetti; Marina Vivarelli; Manuela Colucci; Simona Cascioli; Enrico Bertini
Journal:  Eur J Paediatr Neurol       Date:  2011-09-07       Impact factor: 3.140

Review 7.  Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature.

Authors:  L Benedetti; C Briani; D Franciotta; R Fazio; I Paolasso; C Comi; M Luigetti; M Sabatelli; F Giannini; G L Mancardi; A Schenone; E Nobile-Orazio; D Cocito
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

Review 8.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Pieter A van Doorn; Richard A C Hughes
Journal:  Cochrane Database Syst Rev       Date:  2013-06-14

9.  Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era.

Authors:  Tyson L Ware; Andrew J Kornberg; M Victoria Rodriguez-Casero; Monique M Ryan
Journal:  J Child Neurol       Date:  2013-01-29       Impact factor: 1.987

Review 10.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154
View more
  7 in total

Review 1.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 2.  Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Anna Lena Fisse; Jeremias Motte; Thomas Grüter; Melissa Sgodzai; Kalliopi Pitarokoili; Ralf Gold
Journal:  Neurol Res Pract       Date:  2020-12-08

3.  Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study.

Authors:  Jeremias Motte; Anna Lena Fisse; Nuray Köse; Thomas Grüter; Hannah Mork; Diamantis Athanasopoulos; Miriam Fels; Susanne Otto; Ines Siglienti; Christiane Schneider-Gold; Kerstin Hellwig; Min-Suk Yoon; Ralf Gold; Kalliopi Pitarokoili
Journal:  Ther Adv Neurol Disord       Date:  2021-03-05       Impact factor: 6.570

Review 4.  Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Authors:  Jianian Hu; Chong Sun; Jiahong Lu; Chongbo Zhao; Jie Lin
Journal:  J Neurol       Date:  2021-06-12       Impact factor: 4.849

5.  Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy.

Authors:  Petra Huehnchen; Wolfgang Boehmerle; Matthias Endres
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

6.  Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

Authors:  Shinobu Shimizu; Masahiro Iijima; Yuki Fukami; Natsuko Tamura; Masahiro Nakatochi; Masahiko Ando; Ryoji Nishi; Haruki Koike; Kenichi Kaida; Michiaki Koga; Takashi Kanda; Hidenori Ogata; Jun-Ichi Kira; Masahiro Mori; Satoshi Kuwabara; Masahisa Katsuno
Journal:  JMIR Res Protoc       Date:  2020-04-01

Review 7.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.